CorrectSequence Therapeutics

CorrectSequence Therapeutics (Correctseq) aims to use our innovative base editing technology to help people with severe diseases.

[CorrectSequence Therapeutics @Correctseq]

High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease @Biospace https://t.co/1092EpLBia

[CorrectSequence Therapeutics @Correctseq]

Milestone achieved! The first SCD patient treated in China with our high-precision base-editing therapy CS-206 has remained VOC-free for >15 months post-engraftment, achieving the primary efficacy endpoint. No product-related AEs have been observed to date. #SCD #BaseEditing

[CorrectSequence Therapeutics @Correctseq]

📢We will give 2 poster presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting, taking place May 11 – 15, 2026, in Boston, MA and online. 📰Poster #1506, 05/12. 📰Poster #3411, 05/14. @ASGCTherapy #GeneEditing #ASGCT2026

[CorrectSequence Therapeutics @Correctseq]

Proud moment for CS-101 🚀
Published in @Nature on April 8, CS-101 enabled β-thal patients to achieve rapid, durable transfusion independence after a single treatment, with strong safety signals.https://t.co/O1KP1XNXy9

[CorrectSequence Therapeutics @Correctseq]

A ‘cure’ for five blood disease patients suggests Chinese genetic medicine can compete globally https://t.co/vgmQcFpcTW

[CorrectSequence Therapeutics @Correctseq]

Base Editing Shows Early Promise for Treating Beta Thalassemia https://t.co/RaCZdbbgF3 via @Inside_PM

[CorrectSequence Therapeutics @Correctseq]

📢We will give a poster presentation at the 67th American Society of Hematology Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida, and online.
📄Poster #6090
🗓 Dec 8, 6–8 PM EST
📍OCCC-West Halls B3-B4 #ASH25 @ASH_hematology #GeneEditing

[CorrectSequence Therapeutics @Correctseq]

📢 Breakthrough in gene editing!
@Correctseq CS-121, targeting APOC3, successfully treated the first chylomicronemia patient — TG levels dropped significantly within 3 days after a single low-dose, with no adverse events. https://t.co/3AG50Men1v #GeneEditing #biotech

[CorrectSequence Therapeutics @Correctseq]

🚀 WORLD FIRST: Correctseq's CS-121 has completed dosing of first chylomicronemia patient, demonstrating excellent safety and significant efficacy. It's the world’s first gene-editing therapy targeting APOC3 for hyperlipidemia. A major milestone for #GeneEditing #Hyperlipidemia

[CorrectSequence Therapeutics @Correctseq]

📢Breakthrough! Our CS-101 base-editing therapy achieved the first clinical cure of sickle cell disease (SCD) in China.
✅Patient showed sustained HbF↑, HbS↓, HbF:HbS=6.5:3.5(the 6th months), Hb>120 g/L.
💪6 months crisis-free & back to normal life.https://t.co/0fZUAwZyxs

[CorrectSequence Therapeutics @Correctseq]

At #EHA2025 in #Milan this week? Jia Chen, Ph.D., Professor and Director, Gene Editing Center, ShanghaiTech University, Co-founder of Correctseq, will give an oral presentation at 11:00~12:15(CEST), June 15, 2025. @EHA_Hematology

[CorrectSequence Therapeutics @Correctseq]

Chinese treatment cures Pakistani girl @ChinaDaily https://t.co/semrUQMel1
🚀Phase 1 enrollment complete for CS-101 gene-editing therapy treating β-thalassemia! Ongoing IIT trials for sickle cell disease & β-thalassemia (NCT06328764, NCT06065189, NCT06565026) #ClinicalTrials

[CorrectSequence Therapeutics @Correctseq]

🧬Breakthrough by #Correctseq Sci-Founders Profs. Chen Jia (@ShanghaiTechUni ) & Yang Li(Fudan Uni) developed #RtABE:
✅ Achieves unprecedented editing precision
✅Opens doors for genetic disease therapies @NatureBiotech
👉Explore: https://t.co/SdMFowk1UH

[CorrectSequence Therapeutics @Correctseq]

🚀 #Mitochondrial DNA Editing Breakthrough @NatureBiotech
Prof. Chen Jia (@Correctseq Sci-Founder) & team @ShanghaiTechUni unveiled:
✅ Solved TALED mechanism puzzle
✅ Created precision mitochondrial editors (eTALED6s)
🔗 https://t.co/a5fqnijmsb

[CorrectSequence Therapeutics @Correctseq]

🌏🧬 BREAKING: Our base editing therapy CS-101 hits new milestone in β-thalassemia treatment! Successfully treated 2nd overseas patient - a Malaysian with transfusion-dependent β-thalassemia. 🩸✨ #GeneEditingTherapy #TDT #thalassemia #GlobalHealth

[CorrectSequence Therapeutics @Correctseq]

@ShLetsMeet 👏👏👏

[CorrectSequence Therapeutics @Correctseq]

👏👏✊✊😀😀

[Shanghai Let's meet @ShLetsMeet]

#Shanghai-based CorrectSequence Therapeutics (#Correctseq) has partnered with the First Affiliated Hospital of #Guangxi Medical University to apply base editing therapy to successfully free a Lao patient suffering from β-thalassemia from dependence on blood transfusions for over 2 months.

It was China’s first successful attempt to use the therapy to cure a foreign patient, which will bring hope to the complete cure of β-hemoglobinopathies patients worldwide. @Correctseq

[Shanghai Let's meet @ShLetsMeet]

#Shanghai-based CorrectSequence Therapeutics (#Correctseq) has partnered with the First Affiliated Hospital of #Guangxi Medical University to apply base editing therapy to successfully free a Lao patient suffering from β-thalassemia from dependence on blood transfusions for over 2 months.

It was China’s first successful attempt to use the therapy to cure a foreign patient, which will bring hope to the complete cure of β-hemoglobinopathies patients worldwide. @Correctseq

[CorrectSequence Therapeutics @Correctseq]

We are excited to announced a significant milestone in our base editing therapy CS-101. Utilizing our pioneering transformer Base Editor (tBE), we have successfully cured the first overseas patient with transfusion-dependent β-thalassemia in the clinical trial.

[CorrectSequence Therapeutics @Correctseq]

Recently, as the world's first base editing therapy for hemoglobinopathies, CS-101 of @Correctseq was included in the EHA2024 Scientific Congress Report for its safe and efficient base editing technology and the promising clinical results.@EHA_Hematology